GeoVax Labs, Inc.
Industry
- Pharmaceuticals
- Drug Delivery
- Vaccines
- Biotechnology
Other Names/Subsidiaries
- Dauphin Technology, Inc.
Latest on GeoVax Labs, Inc.
Biohaven’s stock price closed down 15.2% at $19.84 on 25 April on the news that the company withdrew its application for European Medicines Agency approval of troriluzole in the treatment of spinocere
GeoVax Labs, Inc. is aiming for the underserved niche of immunocompromised people who are unable to benefit from the current crop of US Food and Drug Administration-authorized COVID-19 vaccines with
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AiPharma Joins Effort To Develop Fujifi
Vaccines are a hot area of development and investment, spurred by renewed awareness of the critical public health role they play and the enormous commercial success of the COVID-19 vaccines that have